会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NEW DERIVATIVES OF PYRIDIL PIPERAZINE OR PYRIDAZINYL PIPERAZYL, PROCESS FOR PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THESE COMPOUNDS
    • 新的吡啶基或 哒嗪基,哌嗪衍生物,其制造方法相同,并且含药物
    • WO9624581A2
    • 1996-08-15
    • PCT/EP9600524
    • 1996-02-08
    • BOEHRINGER MANNHEIM GMBHTSAKLAKIDIS CHRISTOSMERTENS ALFREDZIMMERMANN GERDSCHAEFER WOLFGANGDOERGE LIESEL
    • TSAKLAKIDIS CHRISTOSMERTENS ALFREDZIMMERMANN GERDSCHAEFER WOLFGANGDOERGE LIESEL
    • C07D237/20A61K31/495A61K31/50A61P7/02C07D213/74C07DA61K
    • C07D213/74
    • Compounds of formula (I), in which R stands for hydrogen, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, a possibly substituted mono-or bi-cyclic aryl, a possibly substituted hetaryl, a possibly substituted aryl alkyl or one of the groups -OR , -NR R , W stands for nitrogen or -CR , X, Z independently of each other stands for nitrogen or -CH, and where W stands for a nitrogen atom, X must be the group -CH, A stands for a valency bond or the carbonyl group, B stands for a valency bond or a C1-C6 alkyl chain possibly substituted once or several times by lower alkyl or an OR group, D stands for a valency bond, and, where X is a nitrogen atom, can also be the carbonyl group, A, B and D being unable to represent the valency bond simultaneously, R stands for hydrogen, lower alkyl or aryl alkyl, R , R independently of each other stand for hydrogen or lower alkyl, or form a five- or six-membered heterocyclic ring together with the nitrogen atom to which they are linked, R stands for hydrogen or a group OR . The invention also relates to a process for the production of these compounds, and medicaments containing them for the treatment of diseases which are attributable to thromboembolic conditions.
    • 式(I),其中R <1>是氢,低级烷基,低级烯基,环烷基,环烯基的化合物,任选取代的单环或双环芳基,任选取代的杂芳基,任选取代的芳基烷基或以下基团之一-OR < 2>,-NR <3> [R <4>中,W为氮或-CR <5>,X,Z独立地为氮或-CH,以及用于其中W代表氮原子的情况下,X为基团 - 一个必须是CH,表示价键或羰基,B代表被低级烷基或一个或或多取代C1-C6亚烷基链价键或任选的单 - <2>基,D表示化合价键,并且在壳体 在于X是氮原子,也可以是羰基,其中A,B和D不能同时意味着价键,R <2>是氢,低级烷基或芳烷基,R <3>,R <4>独立地是氢, 或妮 ederes烷基,或与氮原子一起形成它们所连接形成五至六元杂环,R <5>是氢或基团或<2>,它们的制备方法和含有这些化合物的药物组合物 用于治疗疾病的那是由于血栓栓塞事件。
    • 7. 发明申请
    • PYRIMIDIN-2,4,6-TRION DERIVATIVES AND THEIR USE AS METALLOPROTEASE-INHIBITORS
    • 嘧啶-2,4,6- TRION衍生物及其作为金属蛋白酶抑制剂
    • WO9858915A3
    • 1999-05-14
    • PCT/EP9803740
    • 1998-06-19
    • ROCHE DIAGNOSTICS GMBHGRAMS FRANKZIMMERMANN GERD
    • GRAMS FRANKZIMMERMANN GERD
    • A61K31/505A61K31/506A61P9/00A61P9/12A61P43/00C07D239/60C07D239/62C07D403/04C07D403/12
    • C07D239/60
    • The invention relates to substances of general formula (I), where R1 and R2, independently of each other, can be H, alkenyl or alkyl, R3 is a W-V group, where W is a bond or a linear or branched alkyl group, which is optionally interrupted by oxygen, sulphur or nitrogen and can be substituted with hydroxy-, amino-, mercapto-, alkoxy-, oxo-, carboxy-, acyl-, alkyl-, aralkyl-, aryl- or heteroaryl groups, and in which V is H, a monocyclic or bicyclic, saturated or unsaturated ring, which can possibly contain between 1 and 4 nitrogen, oxygen or sulphur atoms and can be optionally substituted with hydroxy-, amino-, mercapto-, alkoxy-, oxo-, carboxy-, acyl-, acylamido-, alkyl-, aralkyl-, aryl- or heteroaryl groups; R4 is an -N(R13)-C(O)-R5, -N(R13)-C(O)-OR5, -N(R13)-SO2-R5, -N(R13)-C(S)-R5, -N(R13)-C(S)-OR5, -N(R13)-C(O)-CR14R15(-CR16R17)n -C(O)-R5, or -N(R13)-CR14R15(-CR16R17)n-C(O)-R18 rest, which in each case is linked by the nitrogen atom to the central pyrimidin ring; n is 0 or 1; R13 has the meaning given above for R3 or with R14 or R16 possibly forms a heterocycle having between 4 and 7 members; and R5 is an alkyl-, cycloalkyl-, aralkyl-, aryl- or heteroaryl rest, whereby these rests can be substituted with hydroxy-, amino groups or halogen. R14, R15, R16 and R17, independently of each other, are hydrogen, the C alpha radical of a proteinogenic amino acid, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl, and R14 and R15 or alternatively R16 and R17 can together form a carbocycle having between 3 and 7 members; R18 is OH or N(R6R7), where R6 can be H, alkyl, cycloalkyl, aralkyl, aryl or heteroaryl and R7 is a group which, together with the N atom, represents a proteinogenic or non-proteinogenic alpha or beta amino acid or amino acid amide. In addition, R6 and R7 can together form a ring having between 4 and 7 members, which optionally contains heteroatoms such as oxygen, sulphur or nitrogen and is optionally substituted with alkyl, aralkyl, aryl or heteroaryl. The invention further relates to pharmacologically compatible salts and esters of general formula I and the use of these compounds for manufacturing medicinal products.
    • 因此,本申请是通式(I),其中R 1和R 2可以独立地为H,烯基或烷基的化合物,R 3代表基团WV,其中W是一个键或直链或支链烷基或链烯基 其可任选被氧,硫或氮被中断基,可被羟基,氨基,巯基,烷氧基,氧代,羧基,酰基,烷基,芳烷基,芳基或杂芳基和V为H被取代, 单环或双环,饱和或不饱和环,其可以任选地含有1至4个氮,氧或硫原子,并且任选被羟基,氨基,巯基,烷氧基,氧代,羧基,酰基,酰氨基,烷基取代的 基,芳烷基,芳基或杂芳基可以被取代,R 4为基团-N(R 13)-C(O)-R 5,-N(R 13)-C(O)-OR 5,-N(R 13)-SO 2 R 5, -N(R13)-C(S)-R 5,-N(R 13)-C(S)-OR 5,-N(R 13)-C(O)-CR14R15(-CR16R17)NC(O)-R 5,O- 可以是-N(R13)-CR14R15(-CR16R17)NC(O)-R18,每种情况下,通过在中央ř阿伦嘧啶环中的氮原子键合,n为0或1,R13如以上对R 3具有限定 或任选被R14或R16连接形成4-至7-元杂环且R 5是烷基,环烷基,芳烷基,芳基或杂芳基,其中这些基团可以被羟基,氨基或卤素取代。 R14,R15,R16和R17独立地表示氢,蛋白氨基酸,烷基,环烷基,芳基,杂芳基,芳烷基或杂芳烷基的基团碳原子α-; R14和R15,或者R16和R17可以一起形成3至7元碳环,R18是OH或N(R 6 R 7),其中R 6可以是H,烷基,环烷基,芳烷基,芳基或杂芳等于和R 7为基团 是一个蛋白原或非蛋白原的阿尔法与N原子一起 - 或β氨基酸或氨基酸酰胺是并且也R6和R7可以形成4〜7元环,任选地含有杂原子如氧,硫或氮 就可以了,任选被烷基,芳烷基,芳基或杂芳基取代。 此外,药理学上可接受的盐和通式结构(I)为w ELL作为使用这些化合物用于生产药物的酯。